Medical Device, Pharma & Investment Advisory Services
Dr. Wei Phin Tan is a board-certified urologic oncologist, active clinical trialist, principal investigator, and published investigator at NYU Langone Health. He advises medical device companies, pharmaceutical companies, diagnostics companies, venture capital firms, and private equity groups on product development, clinical trial design, market positioning, and investment diligence in urologic oncology.
His clinical practice spans prostate cancer, kidney cancer, bladder cancer, focal therapy, robotic surgery, transperineal biopsy, molecular imaging, and intravesical therapies. This gives him a practical view of how technologies perform not only in trials, but also in real-world clinical workflows.
Where Dr. Tan Adds Value
Medical Device Companies
Focal ablation platforms, biopsy systems, robotic surgery, image-guided interventions, hydrogel spacers, and surgical imaging technologies. Engagements include KOL advisory boards, product development feedback, clinical workflow mapping, regulatory strategy, study design, and principal investigator roles.
Pharmaceutical Companies
Bladder cancer, prostate cancer, intravesical therapies, androgen receptor pathway inhibitors, immunotherapy, radiopharmaceuticals, PET imaging agents, genomics, and biomarker-driven treatment strategies. Engagements include scientific advisory boards, investigator-initiated studies, trial feasibility, site activation, and market access insight.
Venture Capital & Private Equity
Clinical diligence, market sizing, technology differentiation, competitive landscape analysis, KOL network mapping, clinical adoption barriers, and post-investment strategy across urologic oncology devices, diagnostics, therapeutics, and AI-enabled platforms.
Areas of Deep Expertise
Selected Industry Collaborations
Dr. Tan has served as investigator, principal investigator, advisor, or collaborator on studies or programs involving:
Prostate Cancer Treatment Landscape
Prostate cancer is moving away from a one-size-fits-all model. The modern landscape now spans active surveillance, focal therapy, robotic prostatectomy, radiation, molecular imaging, genomic risk stratification, androgen receptor pathway inhibitors, radiopharmaceuticals, PARP inhibitors, immunotherapy, and AI-enabled decision support.
Dr. Tan advises companies and investors across this full continuum, from early detection and localization to focal therapy, definitive treatment, biochemical recurrence, metastatic hormone-sensitive disease, and metastatic castration-resistant prostate cancer.
Localized Prostate Cancer
Active Surveillance
Active surveillance remains a critical strategy for carefully selected low-risk and favorable intermediate-risk prostate cancer. The key commercial and clinical opportunity is not simply "watching" cancer, but improving risk stratification with MRI, transperineal biopsy, genomics, AI pathology, and longitudinal surveillance tools.
Advisory focus: patient selection, monitoring protocols, MRI/biopsy intervals, escalation triggers, patient anxiety, adherence, and real-world barriers to surveillance adoption.
Focal Therapy
Focal therapy is one of the most active areas of prostate cancer device innovation. Technologies include HIFU, cryoablation, pulsed electric field therapy, irreversible electroporation, laser ablation, and emerging noninvasive or image-guided ablation platforms.
Dr. Tan performs focal therapy and evaluates technologies based on lesion location, ablation geometry, image guidance, safety margins, functional preservation, retreatment strategy, and workflow integration.
Advisory focus: focal therapy device differentiation, ideal candidate profiles, treatment-planning software, biopsy and imaging requirements, clinical endpoints, retreatment pathways, and reimbursement strategy.
Robotic Prostatectomy
Robotic prostatectomy remains a key whole-gland treatment for localized prostate cancer, particularly for patients who want definitive pathology, nodal staging when appropriate, and durable local control. The next frontier is functional preservation, including nerve-sparing, bladder neck preservation, urethral length preservation, continence recovery, and same-day discharge pathways.
Advisory focus: robotic surgery innovation, surgical imaging, margin assessment, anastomotic technologies, continence recovery, same-day discharge workflows, and post-prostatectomy monitoring.
Radiation Oncology Support
Radiation therapy continues to evolve through SBRT, MR-guided radiation, brachytherapy, proton therapy, fiducial tracking, rectal spacers, and image-guided planning. Rectal spacers and fiducials are increasingly important workflow components for radiation precision and toxicity reduction.
Advisory focus: hydrogel spacers, fiducial placement, MR-Linac workflows, CyberKnife requirements, CT/MRI visibility, referral pathways, and urology-radiation oncology coordination.
Prostate Cancer Diagnostics & Imaging
Transperineal MRI Fusion Biopsy
The diagnostic pathway is shifting from transrectal biopsy toward transperineal biopsy because of infection reduction, improved anterior sampling, and better alignment with MRI-targeted diagnosis. The PREVENT randomized trial showed no infections in the transperineal group without prophylactic antibiotics, compared with infections in the transrectal biopsy group despite targeted prophylaxis.
Advisory focus: biopsy platform design, local anesthesia workflows, fusion accuracy, office-based adoption, patient tolerance, training curves, device economics, and antibiotic stewardship.
PSMA PET Imaging
PSMA PET has transformed staging, biochemical recurrence detection, surgical planning, radiation planning, and patient selection for radioligand therapy. It is now central to the prostate cancer ecosystem, especially as PSMA-positive disease becomes a gateway to targeted radiopharmaceutical treatment.
Advisory focus: PSMA PET tracer selection, PET/MRI integration, recurrence mapping, focal therapy failure detection, radiopharmaceutical referral pathways, and imaging-based trial endpoints.
Genomics, AI, and Risk Stratification
The market is rapidly expanding beyond traditional clinicopathologic variables. Tissue genomics, germline testing, AI pathology, imaging AI, and multimodal risk models are increasingly used to identify which patients need surveillance, focal treatment, surgery, radiation, systemic intensification, or clinical trials.
Advisory focus: clinical utility, adoption barriers, report design, workflow integration, physician trust, patient-facing communication, and reimbursement.
Advanced Prostate Cancer Landscape
Biochemical Recurrence
Biochemical recurrence is now a major drug development and imaging opportunity. Enzalutamide was FDA-approved in 2023 for nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis, expanding androgen receptor pathway inhibition into an earlier disease state.
Advisory focus: BCR risk stratification, PSMA PET-directed treatment, ARPI use, intermittent versus continuous therapy, patient selection, and trial design.
Metastatic Hormone-Sensitive Prostate Cancer
The standard of care has shifted from ADT alone to treatment intensification with androgen receptor pathway inhibitors, with or without docetaxel depending on patient risk, disease volume, and fitness. Darolutamide received an expanded FDA approval in 2025 for metastatic castration-sensitive prostate cancer, including use with ADT based on ARANOTE, after prior approval in combination with docetaxel.
Advisory focus: ARPI differentiation, triplet versus doublet therapy, patient selection, toxicity positioning, sequencing, and real-world adoption.
Metastatic Castration-Resistant Prostate Cancer
The mCRPC space is increasingly segmented by PSMA expression, homologous recombination repair mutations, prior ARPI exposure, prior taxane exposure, symptoms, marrow reserve, and patient goals.
Pluvicto's FDA indication was expanded in 2025 to include adults with PSMA-positive mCRPC previously treated with an ARPI who are appropriate to delay taxane-based chemotherapy, moving radioligand therapy earlier in the treatment sequence.
Advisory focus: PSMA-positive patient identification, radioligand sequencing, taxane-sparing strategies, PARP inhibitor positioning, combination therapy, referral pathways, and community adoption.
Radiopharmaceuticals
Radioligand therapy is one of the most important growth areas in prostate cancer. The commercial and clinical questions are shifting from "does it work?" to "which patient, which sequence, which combination, and how early?"
Advisory focus: PSMA PET eligibility, nuclear medicine capacity, urology-medical oncology referral pathways, sequencing before or after chemotherapy, combinations with ARPI or PARP inhibition, and trial endpoint selection.
NMIBC Therapeutic Landscape
Dr. Tan advises on the rapidly evolving non-muscle-invasive bladder cancer treatment space, including BCG, intravesical chemotherapy combinations, systemic immunotherapy, gene therapy, cytokine-based immunotherapy, and drug-device delivery systems. He is the NYU site Principal Investigator on the ECOG-ACRIN BRIDGE trial comparing intravesical gemcitabine plus docetaxel versus BCG in BCG-naïve high-risk NMIBC. BRIDGE is a randomized phase 3 trial evaluating GEMDOCE against standard BCG in this setting.
BCG
Intravesical BCG remains the standard first-line treatment for many patients with high-risk NMIBC. Advisory work includes BCG supply strategy, induction and maintenance regimens, toxicity management, patient adherence, and sequencing after recurrence.
Gemcitabine + Docetaxel
Gemcitabine plus docetaxel is one of the most important intravesical chemotherapy regimens in NMIBC, supported by strong real-world adoption and now being tested head-to-head against BCG in the phase 3 BRIDGE trial.
Pembrolizumab
Pembrolizumab is FDA-approved for selected patients with BCG-unresponsive high-risk NMIBC with carcinoma in situ who are ineligible for or decline cystectomy. Advisory work includes patient selection, systemic toxicity counseling, bladder-preservation pathways, and sequencing against intravesical alternatives.
Adstiladrin
Adstiladrin, nadofaragene firadenovec-vncg, is an adenoviral vector-based gene therapy approved for high-risk BCG-unresponsive NMIBC with CIS with or without papillary tumors.
Anktiva
Anktiva, nogapendekin alfa inbakicept-pmln, was FDA-approved in 2024 in combination with BCG for BCG-unresponsive NMIBC with CIS with or without papillary tumors.
Inlexzo
Inlexzo is an intravesical drug delivery system designed to provide sustained gemcitabine exposure. Advisory focus includes patient selection, office logistics, drug-device workflow, BCG-unresponsive and BCG-naïve positioning, and integration into bladder-sparing treatment algorithms.
Zusduri
Zusduri, mitomycin intravesical solution, was FDA-approved in 2025 for adults with recurrent low-grade intermediate-risk NMIBC.
Emerging Pipeline
Dr. Tan advises on emerging NMIBC assets including novel intravesical delivery systems, gene therapies, immunotherapy combinations, cytokine-based therapies, hyperthermia-enhanced chemotherapy, AI cystoscopy, urine biomarkers, and perioperative treatment strategies.
Advisory, consulting, and diligence engagements are performed in accordance with institutional conflict-of-interest policies and applicable regulatory requirements.
Industry relationships are disclosed where required and do not determine individual patient recommendations. Clinical decisions are based on patient-specific anatomy, cancer risk, evidence, and shared decision-making.
Start an Engagement
Reach out for KOL work, advisory boards, clinical trial leadership, scientific advisory, or investment diligence in urologic oncology.